Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2020 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

The 2020 "Prescrire Prize" is awarded in Paris to   3 noteworthy books about health and healthcare The recipients of the 2020 "Prescrire Prize" book awards were announced on 1 October 2020. The prize is awarded to works of particular interest to the general public and/or healthcare professionals. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Apixaban, edoxaban, rivaroxaban: situations with a high risk of bleeding or thrombosis FEATURED REVIEW When using xabans, it is essential to take into account the situations that increase the risk of bleeding or thrombosis, and to monitor the patient for any change in these risks, such as new comorbidities, new drugs, or discontinued drugs. Full review (4 pages) available for download by subscribers. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the October issue of Prescrire International: A public awareness campaign which mainly benefits companies FREE DOWNLOAD The pharmaceutical company Abbvie, which markets adalimumab (Humira°), has jointly funded a public awareness campaign produced by the patient organisation France Psoriasis. Objective: marketing. Full text available for free download. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 patients who are not hospitalised: anticoagulation is rarely justified  NEWS UPDATE  The risk of thromboembolism in patients with a mild to moderate form of covid-19 is unclear and probably varies greatly between patients. Is anticoagulation justified to prevent deep vein thrombosis in patients with covid-19 who are not hospitalised? 24 September 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Proton pump inhibitors: increased risk of severe covid-19  NEWS UPDATE  Proton pump inhibitors (PPIs) are known to increase the risk of various infections, including pneumonia and pseudomembranous colitis. What about covid-19 infection? A recent study yields some useful information. 15 September 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 1 September 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Hydroxychloroquine: the situation is critical EDITORIALAccording to the methodological principles of clinical evaluation, comparative trials provide the most reliable evidence when evaluating treatments. The lowest-level evidence comes from expert opinions, case series, other observational studies and empiricism. This is still true in 2020 – and also in covid-19. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Gentian violet used when breastfeeding: irritant and carcinogenic Gentian violet has no place in the treatment of nipple thrush while breastfeeding, nor of oral thrush in the newborn baby. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Pinworm infection: easy to detect and easy to treat Anal itching at night is highly suggestive of pinworm infection, an intestinal parasitic infection that is very common in children. Several drugs, none of which have serious adverse effects, eradicate the parasites, after two doses, given two weeks apart. 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire’s response to the EC's consultation on the pharmaceutical strategy roadmap  ADVANCING HEALTHCARE POLICY  The pharmaceutical strategy for Europe, to be published by the European Commission (EC) before the end of the year, should centre on transparency and robust evidence, support public health priorities and ensure evidence-based independent policy elaboration, assessments and surveillance of medicines and full access to clinical data 07 July 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2020", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly journal written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 August 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Atezolizumab as an adjunct to cytotoxic drugs in lung cancer • Dapagliflozin in type 1 diabetes: serious harms • Valproic acid during pregnancy: effects on the third generation? • Doxylamine during pregnancy • Should blood pressure-lowering drugs be taken at bedtime?... > Subscribe now 1 October 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 September 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 September 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page